Antengene's Commitment to Innovative Treatment Solutions
Here at Antengene Corporation Limited, we are dedicated to bringing forward-thinking medical solutions to patients who truly need them. Recently, we celebrated an important milestone as the Malaysian National Pharmaceutical Regulatory Agency granted approval for our innovative treatment, XPOVIO® (selinexor). This marks a pivotal development in the fight against diffuse large B-cell lymphoma (DLBCL), particularly for adult patients that have faced multiple lines of therapy without success.
Understanding the Approval for DLBCL
The approval signifies that XPOVIO® may now be used for individuals suffering from relapsed or refractory DLBCL who are ineligible for autologous stem cell transplant. This is a significant patient population seeking better therapeutics. Having received two previous indications in Malaysia, XPOVIO® now offers multiple options in treatment arenas, including both DLBCL and multiple myeloma (MM). Prior to this expansion, it had already proven its effectiveness when combined with bortezomib and dexamethasone for those diagnosed with MM after at least one line of therapy. Furthermore, it also proved beneficial for patients with more advanced MM, having undergone extensive previous treatments.
XPOVIO®: A Game-Changer in Oncology
What sets XPOVIO® apart is its groundbreaking mechanism of action. As the first and only orally-available, selective XPO1 inhibitor, it represents a novel approach to cancer treatment. Its ability to target and inhibit specific pathways within cancer cells gives new hope to patients where traditional therapies might not be enough. With approvals across ten regions within the Asia-Pacific area, we anticipate even wider acceptance and integration into public health insurance systems in the near future, making it increasingly accessible to those battling cancer.
Antengene's Ongoing Innovations and Pipeline
The work we are doing at Antengene goes beyond just the approval of one drug. Our focused efforts encompass multiple therapeutics that are designed to address unmet medical needs within various therapeutic areas. Our pipeline includes innovative candidates like ATG-022, ATG-037, and ATG-101, each one representing hope for patients dealing with serious health challenges. Furthermore, our proprietary AnTenGager™ platform highlights our commitment to advancing treatments for both solid tumors and hematological malignancies, showcasing our innovative approach in therapy development.
Our Journey So Far
Since our inception, Antengene has been dedicated to advancing research and development, having achieved 32 investigational new drug (IND) approvals in both the United States and across Asia. Our leading therapeutic asset, XPOVIO®, is now approved in numerous countries, including Mainland China, Hong Kong, and Singapore, and has been included in the national insurance schemes of several key markets. As we continue to expand and enhance our offerings, we look forward to making a positive impact on the lives of patients globally.
Frequently Asked Questions
What is XPOVIO® used for?
XPOVIO® is primarily indicated for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) among other approved uses for multiple myeloma.
How does XPOVIO® work?
XPOVIO® is a selective XPO1 inhibitor that works to inhibit pathways within cancer cells, thus providing a novel therapeutic option.
In which countries is XPOVIO® approved?
XPOVIO® has gained approval in multiple countries in the Asia-Pacific region, including South Korea, Singapore, and Australia.
What impact does this approval in Malaysia have?
This approval expands treatment options available to patients with DLBCL, offering hope to those who have limited options due to previous failed therapies.
What future developments are anticipated for Antengene?
Antengene aims to further develop its innovative pipeline, expanding the reach of its therapeutics while gaining additional approvals across various regions.
